skip to content
Primary navigation


DrugXtandi (enzalutamide) [Astellas Pharma US, Inc.]  

September 2014

Therapeutic area - Oral Oncology

Approval criteria

Diagnosis of metastatic castration-resistant prostate cancer

Quantity limits

  • The initial PA will allow a first fill of 14 days [fifty-six, 40 mg tablets] with one refill to ensure patient tolerance with therapy before approving in larger, monthly quantities
  • Monthly quantity limit = 136


MHCP Provider Call Center 651-431-2700 or 800-366-5411

back to top